Talphera Inc.
Gesloten
0.75 -2.6
Overzicht
Wijziging aandelenprijs
24u
Min
0.73
Max
0.78
Inkomsten | 1.2M -2.6M |
|---|---|
Winstmarge | -443,600 |
Werknemers | 12 |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +306.41% upside |
Volgende Winsten | 13 aug 2026 |
|---|
Marktkapitalisatie | 35M |
|---|---|
Vorige openingsprijs | 3.35 |
Vorige sluitingsprijs | 0.75 |
Talphera Inc. Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Talphera Inc. Prognose
Koersdoel
By TipRanks
306.41% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 3.17 USD 306.41%
Hoogste 3.5 USD
Laagste 3 USD
Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Talphera Inc. - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Winst voor belastingen
Verkoop
Rente-uitgaven op schulden
Operationele winst
$
Over Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
